146 related articles for article (PubMed ID: 16101243)
1. [Tumor suppressor gene PTEN and non-alcoholic steatohepatitis (NASH)].
Sato W; Horie Y; Watanabe S; Suzuki A
Nihon Rinsho; 2005 Aug; 63(8):1475-83. PubMed ID: 16101243
[TBL] [Abstract][Full Text] [Related]
2. Non-alcoholic steatohepatitis and hepatocellular carcinoma: lessons from hepatocyte-specific phosphatase and tensin homolog (PTEN)-deficient mice.
Watanabe S; Horie Y; Kataoka E; Sato W; Dohmen T; Ohshima S; Goto T; Suzuki A
J Gastroenterol Hepatol; 2007 Jun; 22 Suppl 1():S96-S100. PubMed ID: 17567478
[TBL] [Abstract][Full Text] [Related]
3. PTEN in non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and cancer.
Peyrou M; Bourgoin L; Foti M
Dig Dis; 2010; 28(1):236-46. PubMed ID: 20460918
[TBL] [Abstract][Full Text] [Related]
4. [Hepatocyte-specific Pten deficient mice].
Horie Y; Ohshima S; Sato W; Suzuki A; Watanabe S
Nihon Rinsho; 2006 Jun; 64(6):1033-42. PubMed ID: 16768106
[TBL] [Abstract][Full Text] [Related]
5. Eicosapentaenoic acid ameliorates steatohepatitis and hepatocellular carcinoma in hepatocyte-specific Pten-deficient mice.
Ishii H; Horie Y; Ohshima S; Anezaki Y; Kinoshita N; Dohmen T; Kataoka E; Sato W; Goto T; Sasaki J; Sasaki T; Watanabe S; Suzuki A; Ohnishi H
J Hepatol; 2009 Mar; 50(3):562-71. PubMed ID: 19162361
[TBL] [Abstract][Full Text] [Related]
6. Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease.
Clarke JD; Novak P; Lake AD; Shipkova P; Aranibar N; Robertson D; Severson PL; Reily MD; Futscher BW; Lehman-McKeeman LD; Cherrington NJ
Dig Dis Sci; 2014 Feb; 59(2):365-74. PubMed ID: 24048683
[TBL] [Abstract][Full Text] [Related]
7. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas.
Horie Y; Suzuki A; Kataoka E; Sasaki T; Hamada K; Sasaki J; Mizuno K; Hasegawa G; Kishimoto H; Iizuka M; Naito M; Enomoto K; Watanabe S; Mak TW; Nakano T
J Clin Invest; 2004 Jun; 113(12):1774-83. PubMed ID: 15199412
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of the Y220C mutant p53 against steatosis: good news?
Gori M; Barbaro B; Arciello M; Maggio R; Viscomi C; Longo A; Balsano C
J Cell Physiol; 2014 Sep; 229(9):1182-92. PubMed ID: 24395441
[TBL] [Abstract][Full Text] [Related]
9. Increased hepatic oxidative DNA damage in patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma.
Tanaka S; Miyanishi K; Kobune M; Kawano Y; Hoki T; Kubo T; Hayashi T; Sato T; Sato Y; Takimoto R; Kato J
J Gastroenterol; 2013 Nov; 48(11):1249-58. PubMed ID: 23329365
[TBL] [Abstract][Full Text] [Related]
10. Pten signaling in gliomas.
Knobbe CB; Merlo A; Reifenberger G
Neuro Oncol; 2002 Jul; 4(3):196-211. PubMed ID: 12084351
[TBL] [Abstract][Full Text] [Related]
11. [From fatty liver to liver cancer--new development in non-alcoholic steatohepatitis (NASH) using animal models].
Horie Y; Suzuki A; Kataoka E; Goto T; Yoshino R; Sato W; Watanabe S
Nihon Naika Gakkai Zasshi; 2005 May; 94(5):990-8. PubMed ID: 15926473
[No Abstract] [Full Text] [Related]
12. Dual Shp2 and Pten Deficiencies Promote Non-alcoholic Steatohepatitis and Genesis of Liver Tumor-Initiating Cells.
Luo X; Liao R; Hanley KL; Zhu HH; Malo KN; Hernandez C; Wei X; Varki NM; Alderson N; Chu C; Li S; Fan J; Loomba R; Qiu SJ; Feng GS
Cell Rep; 2016 Dec; 17(11):2979-2993. PubMed ID: 27974211
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-α agonist, Wy 14,643, improves metabolic indices, steatosis and ballooning in diabetic mice with non-alcoholic steatohepatitis.
Larter CZ; Yeh MM; Van Rooyen DM; Brooling J; Ghatora K; Farrell GC
J Gastroenterol Hepatol; 2012 Feb; 27(2):341-50. PubMed ID: 21929649
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic steatohepatitis and noncirrhotic hepatocellular carcinoma: fertile soil.
Torres DM; Harrison SA
Semin Liver Dis; 2012 Feb; 32(1):30-8. PubMed ID: 22418886
[TBL] [Abstract][Full Text] [Related]
15. PTPRO-mediated autophagy prevents hepatosteatosis and tumorigenesis.
Zhang W; Hou J; Wang X; Jiang R; Yin Y; Ji J; Deng L; Huang X; Wang K; Sun B
Oncotarget; 2015 Apr; 6(11):9420-33. PubMed ID: 25826083
[TBL] [Abstract][Full Text] [Related]
16. The biology and clinical relevance of the PTEN tumor suppressor pathway.
Sansal I; Sellers WR
J Clin Oncol; 2004 Jul; 22(14):2954-63. PubMed ID: 15254063
[TBL] [Abstract][Full Text] [Related]
17. Regular exercise decreases liver tumors development in hepatocyte-specific PTEN-deficient mice independently of steatosis.
Piguet AC; Saran U; Simillion C; Keller I; Terracciano L; Reeves HL; Dufour JF
J Hepatol; 2015 Jun; 62(6):1296-303. PubMed ID: 25623824
[TBL] [Abstract][Full Text] [Related]
18. Hepatocellular carcinoma and non-alcoholic steatohepatitis: The state of play.
Charrez B; Qiao L; Hebbard L
World J Gastroenterol; 2016 Feb; 22(8):2494-502. PubMed ID: 26937137
[TBL] [Abstract][Full Text] [Related]
19. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
[TBL] [Abstract][Full Text] [Related]
20. Proteomic and lipidomic signatures of lipid metabolism in NASH-associated hepatocellular carcinoma.
Muir K; Hazim A; He Y; Peyressatre M; Kim DY; Song X; Beretta L
Cancer Res; 2013 Aug; 73(15):4722-31. PubMed ID: 23749645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
